PT Mustika Ratu Tbk (IDX:MRAT)
Indonesia · Delayed Price · Currency is IDR 252.00
0.00 (0.00%)
Aug 1, 2025, 3:28 PM WIB
CTI BioPharma Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 342,531 | 333,563 | 300,596 | 285,178 | 326,795 | 318,408 | Upgrade | |
Revenue Growth (YoY) | 13.43% | 10.97% | 5.41% | -12.73% | 2.63% | 4.32% | Upgrade |
Cost of Revenue | 180,102 | 171,717 | 128,342 | 148,294 | 130,266 | 116,835 | Upgrade |
Gross Profit | 162,429 | 161,846 | 172,254 | 136,883 | 196,529 | 201,574 | Upgrade |
Selling, General & Admin | 163,234 | 159,917 | 173,222 | 236,319 | 182,320 | 186,494 | Upgrade |
Other Operating Expenses | -3,477 | -3,393 | 992.35 | -204.75 | -990.34 | 1,484 | Upgrade |
Operating Expenses | 159,757 | 156,524 | 174,214 | 236,114 | 181,330 | 187,978 | Upgrade |
Operating Income | 2,672 | 5,321 | -1,960 | -99,231 | 15,199 | 13,596 | Upgrade |
Interest Expense | -13,625 | -13,686 | -13,866 | -11,733 | -8,179 | -6,603 | Upgrade |
Interest & Investment Income | 5,206 | 5,195 | 5,065 | 430.61 | 11.18 | 23.2 | Upgrade |
Currency Exchange Gain (Loss) | 6,915 | 4,302 | -2,445 | 1,103 | -428.93 | -1,486 | Upgrade |
Other Non Operating Income (Expenses) | 65.58 | 71.86 | 91.34 | 156.75 | 26.03 | 25.26 | Upgrade |
EBT Excluding Unusual Items | 1,234 | 1,205 | -13,115 | -109,273 | 6,628 | 5,555 | Upgrade |
Gain (Loss) on Sale of Assets | 38.59 | 38.59 | -80.23 | 158,710 | 960.39 | 623.82 | Upgrade |
Pretax Income | 1,272 | 1,244 | -13,195 | 49,438 | 7,589 | 6,179 | Upgrade |
Income Tax Expense | 6,284 | 6,363 | 917.69 | -18,374 | 7,231 | 12,946 | Upgrade |
Earnings From Continuing Operations | -5,011 | -5,119 | -14,113 | 67,812 | 357.51 | -6,767 | Upgrade |
Minority Interest in Earnings | -1.82 | -3.31 | -27.34 | 20.98 | 0.62 | 0.51 | Upgrade |
Net Income | -5,013 | -5,123 | -14,140 | 67,833 | 358.13 | -6,766 | Upgrade |
Net Income to Common | -5,013 | -5,123 | -14,140 | 67,833 | 358.13 | -6,766 | Upgrade |
Net Income Growth | - | - | - | 18841.05% | - | - | Upgrade |
Shares Outstanding (Basic) | 428 | 428 | 428 | 428 | 428 | 428 | Upgrade |
Shares Outstanding (Diluted) | 428 | 428 | 428 | 428 | 428 | 428 | Upgrade |
EPS (Basic) | -11.71 | -11.97 | -33.04 | 158.49 | 0.84 | -15.81 | Upgrade |
EPS (Diluted) | -11.71 | -11.97 | -33.04 | 158.49 | 0.84 | -15.81 | Upgrade |
EPS Growth | - | - | - | 18841.06% | - | - | Upgrade |
Free Cash Flow | -4,610 | 3,048 | -27,259 | -75,064 | -9,633 | -24,307 | Upgrade |
Free Cash Flow Per Share | -10.77 | 7.12 | -63.69 | -175.38 | -22.51 | -56.79 | Upgrade |
Gross Margin | 47.42% | 48.52% | 57.30% | 48.00% | 60.14% | 63.31% | Upgrade |
Operating Margin | 0.78% | 1.59% | -0.65% | -34.80% | 4.65% | 4.27% | Upgrade |
Profit Margin | -1.46% | -1.54% | -4.70% | 23.79% | 0.11% | -2.13% | Upgrade |
Free Cash Flow Margin | -1.35% | 0.91% | -9.07% | -26.32% | -2.95% | -7.63% | Upgrade |
EBITDA | 7,115 | 9,593 | 2,706 | -94,462 | 20,930 | 19,122 | Upgrade |
EBITDA Margin | 2.08% | 2.88% | 0.90% | -33.12% | 6.40% | 6.00% | Upgrade |
D&A For EBITDA | 4,443 | 4,272 | 4,666 | 4,769 | 5,731 | 5,526 | Upgrade |
EBIT | 2,672 | 5,321 | -1,960 | -99,231 | 15,199 | 13,596 | Upgrade |
EBIT Margin | 0.78% | 1.59% | -0.65% | -34.80% | 4.65% | 4.27% | Upgrade |
Effective Tax Rate | 493.85% | 511.60% | - | - | 95.29% | 209.51% | Upgrade |
Advertising Expenses | - | 58,361 | 63,476 | 76,971 | 57,226 | 62,322 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.